CLOZAPINE VS HALOPERIDOL IN TREATMENT OF REFRACTORY SCHIZOPHRENIA

氯氮平与氟哌啶醇治疗难治性精神分裂症的比较

• 批准号: 3901022
• 负责人: L B BIGELOW
• 金额: --
• 依托单位: NATIONAL INSTITUTE OF MENTAL HEALTH
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/3901022
• 关键词: clozapine; drug adverse effect; drug metabolism; extrapyramidal disorder; haloperidol; human subject; human therapy evaluation; mental disorder chemotherapy; neuropsychological tests; placebos; prolactin; schizophrenia; single photon emission computed tomography; tranquilizer

Clozapine has ben called and "atypical neuroleptic" because it does not induce the characteristic elevations in prolactin levels not does it produce the extrapyramidal reactions common to "classical" neuroleptics. We are conducting a blinded crossover study comparing clinical and biological response of treatment refractory schizophrenics to clozapine versus haloperidol. When enough patients have been studies we will have clinical, neuropsychological, and SPECT studies of each patient on haloperidol, placebo and clozapine. These results may shed some light on the underlying mechanisms for the often unique clinical responsiveness of patients to clozapine. To date four patients have begun this 18 week protocol; none have completed it.

氯氮平被称为“非典型精神抑制剂”，因为它不 引起催乳素水平的特征性升高， 产生“经典”精神抑制剂常见的锥体外系反应。 我们正在进行一项盲法交叉研究， 难治性精神分裂症患者对氯氮平的生物学反应 与氟哌啶醇的对比 当有足够的病人接受研究时，我们将进行临床， 神经心理学和SPECT研究， 安慰剂和氯氮平。 这些结果可能会揭示一些潜在的 患者通常独特的临床反应机制， 氯氮平 到目前为止，已有4名患者开始了这项为期18周的方案;没有一名患者完成了该方案。 了